Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Compounding Chemotherapy Market Growth From $6.49 Billion In 2026 To $8.2 Billion By 2030 At A CAGR Of 6%
The compounding chemotherapy market has demonstrated substantial growth in recent years. It is projected to increase from $6.11 billion in 2025 to $6.49 billion in 2026, at a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion was driven by factors such as the limited availability of compounding technologies, the rising prevalence of cancer, the reliance on hospital-based compounding, growing awareness of cytotoxic drug safety, and the adoption of manual preparation methods.
The compounding chemotherapy market is set for significant expansion over the next few years, with its size projected to reach $8.2 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 6.0%. This forecasted growth is attributable to factors such as the development of automated and robotic compounding systems, the expansion of chemotherapy services into homecare, increased investment in sterile pharmacy infrastructure, stricter regulatory compliance for personalized medicine, and the proliferation of targeted therapies and immunomodulatory agents. Key trends expected in this period include the growing adoption of personalized chemotherapy formulations, the integration of robotic compounding systems, the expansion of compounding services through homecare and specialty clinics, an increasing focus on sterile and contamination-free environments, and a rising demand for supportive care drug compounding.
Get A Free Sample Report With In-Depth Market Insights:
Compounding Chemotherapy Market Demand Drivers: What’s Powering Industry Growth?
The rising incidence of cancer diagnoses is anticipated to fuel the expansion of the compounding chemotherapy market in the future. Cancer is defined as a collection of illnesses marked by the uncontrolled multiplication and dispersion of aberrant cells throughout the body. This growing occurrence of cancer diagnoses stems mainly from detrimental lifestyle choices like inadequate nutrition, insufficient physical activity, smoking, excessive alcohol intake, and extended contact with environmental contaminants, all of which substantially elevate the chances of developing various forms of cancer. Compounding chemotherapy aids cancer therapy by allowing for customized drug formulations specifically designed for individual patient requirements, thereby boosting effectiveness and reducing adverse reactions. As an illustration, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, averaging 972 per day, an increase of 8,605 from 2022. Consequently, the growing frequency of cancer cases is a significant factor propelling the growth of the compounding chemotherapy market.
Compounding Chemotherapy Market Segment Outlook: Which Categories Are Growing Fastest?
The compounding chemotherapy market covered in this report is segmented –
1) By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
2) By Route Of Administration: Intravenous, Oral, Subcutaneous, Intramuscular, Intrathecal
3) By Technology: With Robotic Arms, Without Robotic Arms
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings
Subsegments:
1) By Cytotoxic Drugs: Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, Topoisomerase Inhibitors
2) By Hormonal Agents: Estrogen Antagonists, Androgen Deprivation Therapy Agents, Aromatase Inhibitors, Progestins, Gonadotropin-Releasing Hormone Agonists
3) By Immunomodulatory Agents: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Interleukins, Cytokines, Immune System Activators
4) By Targeted Therapies: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Poly Polymerase Inhibitors
5) By Supportive Care Drugs: Antiemetics, Erythropoiesis-Stimulating Agents, Bone-Modifying Agents, Pain Management Drugs
Compounding Chemotherapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the compounding chemotherapy market are concentrating on creating innovative solutions, including robotic chemotherapy automation systems, to improve the accuracy, safety, and efficiency involved in preparing personalized cancer treatments. Robotic chemotherapy automation systems are sophisticated devices engineered to precisely and securely prepare customized chemotherapy doses by automating the compounding procedure, thereby minimizing human error and potential contamination risks. As an illustration, in February 2024, Simplivia Healthcare Ltd., an Israel-based healthcare technology company, introduced Smart Compounders Advanced Systems aimed at automating and streamlining the preparation of cytotoxic (chemotherapy) drugs. These systems manage the compounding of cytostatics and antibodies, processing 20 to 40 preparations per hour, and incorporate automatic gravimetric verification and documentation to ensure superior accuracy. They substantially reduce pharmacy staff’s exposure to dangerous substances and are designed for seamless integration into existing laminar airflow (LAF) cabinets or isolators without requiring any modifications.
Compounding Chemotherapy Market Leading Companies And Competitive Benchmarking
Major companies operating in the compounding chemotherapy market are Baxter International Inc., Fresenius Kabi AG, Option Care Health Inc., ICU Medical Inc., Fagron NV, BioScrip Inc., B. Braun Melsungen AG, Medisca Pharmaceutique Inc., Central Admixture Pharmacy Services Inc., Icon Group Holdings Pty Ltd, Avella Specialty Pharmacy, McGuff Compounding Pharmacy Services Inc., Epicur Pharma LLC, PharMEDium Services LLC.
View The Full Compounding Chemotherapy Market Report:
Compounding Chemotherapy Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the compounding chemotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the compounding chemotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model